Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response.

@article{Mlet2013RituximabinducedTC,
  title={Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response.},
  author={Julien M{\'e}let and Denis Mulleman and Ph Goupille and B{\'e}n{\'e}dicte Ribourtout and Herv{\'e} Watier and Guy Thibault},
  journal={Arthritis and rheumatism},
  year={2013},
  volume={65 11},
  pages={2783-90}
}
OBJECTIVE Rituximab, a monoclonal antibody specifically targeting CD20, induces B cell depletion and is effective in the treatment of rheumatoid arthritis (RA). This study was undertaken to evaluate whether routine monitoring of lymphocyte subpopulations, especially T cells, may be useful in patients receiving rituximab for RA. METHODS We examined data on all RA patients receiving rituximab between July 2007 and November 2012 in our center. Peripheral blood CD3+, CD4+, CD8+, CD3-CD56+, and… CONTINUE READING